Targeted Diphtheria Toxin-Based Therapy: A Review Article.

Area of Science:

• Oncology
• Biotechnology
• Toxicology

Background:

• Cancer is a leading global cause of death.
• Conventional therapies often lack specificity, causing side effects.
• Targeted cancer therapies aim to improve efficacy and reduce toxicity.

Purpose of the Study:

• To review diphtheria toxin (DT)-based immunotoxins and suicide-gene therapy strategies.
• To highlight recent developments in targeted cancer treatment using DT.

Main Methods:

• Review of DT-based immunotoxins utilizing targeting moieties (peptides, antibodies, etc.).
• Discussion of suicide-gene therapy involving tumor-specific DT expression.
• Examination of FDA-approved DT-based immunotoxins (Ontak™, Tagraxofusp™).

Main Results:

• DT-based immunotoxins have shown clinical success, with two agents approved by the FDA.
• Suicide-gene therapy strategies are emerging as a promising approach for cancer eradication.
• Targeting moieties enable specific delivery of DT to cancer cells.

Conclusions:

• Diphtheria toxin is a potent agent for targeted cancer therapy.
• Both immunotoxins and suicide-gene therapy represent viable strategies for improved cancer treatment.
• Further research into DT-based therapies holds potential for enhanced anti-cancer efficacy.